Abstract |
A large french multicenter study has been conducted by 750 ophthalmologists with 5,872 patients with open angle chronic glaucoma or intraocular hypertension. The patients were treated twice a day for a period of six months with Betaxolol eye drops, a Beta-1 betablocker product, and cardioselective. Concerning the total population of patients, 35% had a cardiovascular systemic context, 12.1% had a pulmonary systemic context, 5.2% were diabetic patients. Efficacy, systemic tolerance, visual comfort have been evaluated during the study, for each group of patient. After six months of treatment, intra-ocular pressure of the 5,872 patients has been lowered from 22.61 mmHg to 18.25 mmHg. Patients have reported a global efficacy in 97% of cases, a good systemic tolerance in 91% of the cases. The investigations have reported a global efficacy in 96% of cases and a good systemic tolerance in 91%. Ocular comfort has been reported as acceptable by 89% patients and by 92% of the Investigators. The analysis of the results of the study allows us to say that the Beta-blocker-Beta-1 selective eye drop, can be used in treatment of intraocular hypertension or open angle chronic glaucoma with a high range of efficacy and safety.
|
Authors | H Bourgeois |
Journal | Ophtalmologie : organe de la Societe francaise d'ophtalmologie
(Ophtalmologie)
1990 Jul-Aug
Vol. 4
Issue 4
Pg. 323-5
ISSN: 0989-3105 [Print] France |
Vernacular Title | Résultats épidémiologiques et tonométriques d'une étude multicentrique portant sur 5,872 patients avec hypertonie oculaire ou glaucome à angle ouvert traités par le bêtaxolol. |
PMID | 2263381
(Publication Type: Clinical Trial, English Abstract, Journal Article, Multicenter Study)
|
Chemical References |
|
Topics |
- Betaxolol
(therapeutic use)
- Female
- Glaucoma, Open-Angle
(drug therapy, epidemiology, physiopathology)
- Humans
- Male
- Middle Aged
- Ocular Hypertension
(drug therapy, epidemiology, physiopathology)
- Risk Factors
- Tonometry, Ocular
|